Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 5 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus XARELTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 5 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus XARELTO.
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER vs XARELTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III (ATIII) via a unique pentasaccharide sequence, inducing a conformational change that accelerates ATIII-mediated inactivation of factor Xa and thrombin (factor IIa). This prevents fibrin formation and clot propagation. It also inhibits factors IXa, XIa, and XIIa.
Direct factor Xa inhibitor that selectively blocks the active site of factor Xa, inhibiting thrombin generation and thrombus formation.
Continuous IV infusion: Initial bolus of 5,000 units, then 1,000 units/hour (25,000 units/24h) adjusted based on aPTT. Typical infusion rate 10-20 units/kg/hour.
15 mg orally twice daily for 21 days, then 20 mg orally once daily; for atrial fibrillation: 20 mg orally once daily with food; for VTE prophylaxis in hip or knee replacement: 10 mg orally once daily.
None Documented
None Documented
30–150 minutes (intravenous), dose-dependent; at therapeutic doses ~60 minutes; prolonged in hepatic disease.
Terminal elimination half-life: 5–9 hours in young adults, 11–13 hours in elderly (≥65 years). Clinical context: Twice-daily dosing due to relatively short half-life; renal impairment prolongs half-life (up to 15 hours in severe impairment).
Renal: negligible; biliary/fecal: negligible; primarily cleared by hepatic depolymerization and reticuloendothelial system uptake.
Renal (36% as unchanged drug, 30% as inactive metabolites), fecal/biliary (33% as unchanged drug via hepatobiliary route). Total clearance is 10 L/h.
Category A/B
Category C
Anticoagulant
Anticoagulant